dPCR and qPCR Products Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Reagents & Consumables, Instruments, Software), By Application (Clinical Applications, Forensic Applications), By End User (Hospitals & Diagnostic Centres, Research Laboratories & Academic Institutes, Clinical Research Organizations, Others), By Region and Competition, 2020-2030F

Market Overview

The Global dPCR and qPCR Products Market , valued at USD 8.24 Billion in 2024, is projected to experience a CAGR of 7.39% to reach USD 12.64 Billion by 2030. Digital Polymerase Chain Reaction (dPCR) and quantitative Polymerase Chain Reaction (qPCR) products are molecular diagnostic tools for precise nucleic acid detection and quantification. qPCR measures real-time amplification for relative or absolute quantification, while dPCR segments samples for absolute quantification, enhancing sensitivity for scarce targets. Market growth is driven by the rising global prevalence of infectious diseases and genetic disorders, alongside continuous technological advancements improving assay efficiency. Increased adoption in point-of-care diagnostics and personalized medicine also provides momentum. According to the British In-Vitro Diagnostic Association, in 2024, in vitro diagnostics influenced approximately 70% of clinical decisions.

Substantial investments in pharmaceutical research and development further propel market expansion by demanding highly accurate molecular analysis. However, a notable impediment is the high capital expenditure associated with dPCR instrumentation and specialized reagents, potentially limiting broader adoption. Furthermore, increasing competition from alternative molecular diagnostic platforms, such as next-generation sequencing, introduces competitive pressures that may constrain market trajectory.

Key Market Drivers

The increasing global prevalence of infectious diseases and genetic disorders constitutes a primary driver for the dPCR and qPCR products market. These advanced molecular diagnostic tools offer the sensitivity and specificity required for early detection and accurate quantification of pathogens and genetic mutations, which is crucial for effective disease management and public health initiatives. For instance, according to the WHO Global Tuberculosis Report 2024, published on November 1, 2024, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, a notable increase from 7.5 million in 2022, highlighting the persistent and growing burden of infectious diseases that necessitate precise diagnostic solutions. Similarly, the expanding understanding of genetic predispositions and heritable conditions fuels the demand for high-resolution genetic analysis enabled by dPCR and qPCR.

Complementing this demand is the continuous advancement in PCR technology and automation, which significantly enhances assay efficiency, throughput, and reliability. Innovations in instrumentation and reagent chemistry have made PCR platforms more accessible and user-friendly, allowing for broader adoption in diverse clinical and research settings. For example, a study from the UK, reported in the Proceedings of the Clinical Microbiology Open 2024, published March 27, 2025, demonstrated that the automated PCR. Ai system achieved 100% concordance when compared against manual interpretation for a total of 22,200 PCR assay interpretations, illustrating the substantial gains in accuracy and reduced human error facilitated by automation. This technological progress, combined with rising investment, contributes to overall market momentum. According to GenomeWeb, in an article published July 15, 2024, private investment in life science tools and diagnostics firms saw an increase of more than 50 percent in the first six months of 2024 compared to the same period in 2023, underscoring robust financial backing for innovation in this sector.

Download Free Sample Report

Key Market Challenges

High capital expenditure associated with digital Polymerase Chain Reaction (dPCR) instrumentation and specialized reagents presents a significant impediment to the growth of the Global dPCR and qPCR Products Market. The substantial upfront investment required for advanced dPCR systems, coupled with the ongoing costs of specific reagents, creates a financial barrier for potential adopters. This directly constrains market expansion by limiting the accessibility of these technologies to a wider range of laboratories, especially smaller research facilities, clinical diagnostic centers with restricted budgets, and institutions in emerging economies.

The elevated cost of entry particularly affects entities unable to allocate significant funds for new equipment. This financial constraint can lead organizations to defer or forgo the adoption of dPCR and even advanced qPCR solutions, opting instead for less capital-intensive, though potentially less sensitive or precise, diagnostic methods. According to the AdvaMed "Pulse of the Industry: medical technology report," venture financing in the medtech sector experienced a 21% decline in 2023, reaching its lowest levels since 2015-2016, with only 106 venture rounds of US$5 million or higher preceding June 2023. This contraction in available capital directly hinders the ability of laboratories and healthcare providers to invest in high-cost dPCR and qPCR instrumentation, thereby dampening the overall demand for related consumables and services and restricting the installed base of instruments globally.

Key Market Trends

The integration of AI and cloud-based data analytics is transforming PCR workflows, enhancing data processing, interpretation, and accessibility. AI algorithms provide more precise analysis of complex assay results, improving diagnostic accuracy and accelerating turnaround times. Cloud platforms offer scalable solutions for data storage and collaborative research, vital for managing increasing genomic data volumes. QIAGEN, for instance, announced in April 2025 its upcoming QIAsymphony Connect system will integrate digital connectivity and be compatible with QIAsphere, its cloud-based platform for remote monitoring. This market evolution towards sophisticated computational infrastructure is further evidenced by the Association for Molecular Pathology in May 2025, releasing three interrelated Body of Knowledge papers defining essential bioinformatics competencies for clinical diagnostic laboratories.

Expanding applications in liquid biopsy for cancer diagnostics represent a significant growth area for dPCR and qPCR products. These technologies offer non-invasive methods for cancer detection, molecular profiling, and disease monitoring by sensitively detecting circulating tumor DNA and other biomarkers in blood samples. This provides crucial insights for personalized medicine and patient management. Bio-Rad Laboratories, for example, in July 2024 highlighted its advances leveraging Droplet Digital PCR for biopharma and translational research, including collaborations to expand its utility for liquid biopsy applications. The increasing clinical adoption of liquid biopsy assays necessitates standardized procedures, as demonstrated by the Association for Molecular Pathology in October 2023, which published 13 best practice recommendations for validating and reporting these clinical circulating tumor DNA assays.

Segmental Insights

The Reagents & Consumables segment is experiencing rapid growth in the Global dPCR and qPCR Products Market, largely due to their indispensable and recurring nature in every diagnostic and research assay. This continuous demand is fueled by the expanding adoption of dPCR and qPCR technologies across diverse applications, including clinical diagnostics for infectious diseases and oncology, as well as genetic disorder research. Furthermore, technological advancements in reagent formulation, offering enhanced sensitivity and specificity, are crucial for supporting precise results in critical areas like early disease detection and personalized medicine. The necessity for high-quality, standardized reagents for reliable outcomes, often under strict regulatory guidelines for clinical applications, also sustains this growth.

Regional Insights

North America leads the global dPCR and qPCR products market due to its advanced healthcare infrastructure and substantial investment in research and development activities. The region benefits from a high adoption rate of innovative technologies and the presence of key market players who continually introduce new PCR systems and test kits. Furthermore, a supportive regulatory landscape, exemplified by the US Food and Drug Administration's approval of dPCR technology for various applications, fosters market expansion. The increasing prevalence of infectious diseases, genetic disorders, and cancer also drives the demand for accurate and precise diagnostic tools in North America.

Recent Developments

• In July 2025, Bio-Rad Laboratories expanded its Droplet Digital PCR (ddPCR) offerings through a strategic acquisition and the rollout of new platforms. The company launched four new ddPCR platforms, including its QX Continuum™ ddPCR system and the QX700™ series, which were acquired as part of its recent purchase of digital PCR developer Stilla Technologies. This expansion, encompassing over 400,000 assays, created a comprehensive line of digital PCR products for life science research and diagnostic applications. The new platforms enhance workflow simplicity and throughput capabilities across various applications in the global dPCR and qPCR products market.

• In September 2024, QIAGEN launched the QIAcuityDx Digital PCR System, marking a significant expansion of its digital PCR portfolio into clinical diagnostics. This system, which is 510(k) exempt in the U.S. and IVDR-certified in Europe, provides highly precise, absolute quantification of target DNA and RNA, supporting applications such as monitoring cancer progression with liquid biopsies. The launch of QIAcuityDx addresses the evolving needs of clinical laboratories by simplifying workflows and reducing operational costs. This new product aims to strengthen QIAGEN's presence in the clinical segment of the global dPCR products market.

• In June 2024, Stilla Technologies expanded its product portfolio with the introduction of two new digital PCR system configurations for its Nio® product line. These additions, named Nio® E and Nio®, aim to provide digital PCR solutions with varying throughput levels to meet diverse user requirements. The Nio® E configuration offers a throughput of 48 samples per run, while the Nio® model increases this capacity to 192 samples per run, featuring continuous loading capabilities. This expansion in the global dPCR products market emphasizes workflow flexibility, allowing seamless assay transfer across the Nio® family, from occasional users to high-pace routine environments.

• In May 2024, QIAGEN announced a cooperative research and development agreement with the U.S. Federal Bureau of Investigation (FBI). This collaboration focuses on developing a novel digital PCR assay for QIAGEN's QIAcuity devices, specifically for forensic applications. The assay is designed to simultaneously quantify nuclear and mitochondrial DNA concentrations, male DNA, and incorporate quality markers for degradation and inhibition in human samples. This breakthrough research leverages dPCR's high sensitivity and tolerance to inhibitors, significantly improving the success rate of DNA analysis from challenging forensic evidence in the global dPCR products market.

Key Market Players

• Abbott Laboratories, Inc.
• Agilent Technologies, Inc.
• Analytik Jena AG
• Becton Dickinson and Company
• Bio Molecular Systems Pty Ltd
• Biomeme Inc.
• Biomérieux S.A.
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Cole-Parmer Instrument Company LLC

Report Scope:

In this report, the Global dPCR and qPCR Products Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• dPCR and qPCR Products Market , By Product:

• dPCR and qPCR Products Market , By Application:

o   Reagents & Consumables

o   Instruments

o   Software

• dPCR and qPCR Products Market , By End User:

o   Clinical Applications

o   Forensic Applications

• dPCR and qPCR Products Market , By Region:

o   Hospitals & Diagnostic Centers

o   Research Laboratories & Academic Institutes

o   Clinical Research Organizations

o   Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global dPCR and qPCR Products Market .

Available Customizations:

Global dPCR and qPCR Products Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global dPCR and qPCR Products Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]